

Jonathan Kay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6687996/publications.pdf>

Version: 2024-02-01

169
papers

17,610
citations

50276

46
h-index

13379

130
g-index

176
all docs

176
docs citations

176
times ranked

17224
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
2	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.9	2,994
3	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 62-68.	0.9	659
4	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor γ inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. <i>Lancet</i> , The, 2009, 374, 210-221.	13.7	497
5	ACR/EULAR 2010 rheumatoid arthritis classification criteria. <i>Rheumatology</i> , 2012, 51, vi5-vi9.	1.9	353
6	Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.. <i>Journal of Experimental Medicine</i> , 1989, 170, 1133-1148.	8.5	298
7	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008, 58, 964-975.	6.7	266
8	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
9	Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. <i>Arthritis and Rheumatism</i> , 2007, 56, 3433-3441.	6.7	196
10	The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2004, 43, iii2-iii9.	2.3	188
11	Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes.. <i>Journal of Experimental Medicine</i> , 1991, 173, 1511-1520.	8.5	174
12	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.9	173
13	Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 385-404.	1.9	169
14	Nephrogenic systemic fibrosis: Clinicopathological definition and workup recommendations. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1095-1106.e7.	1.2	163
15	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
16	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.9	152
17	Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1081-1091.	0.9	152
18	Imatinib mesylate treatment of nephrogenic systemic fibrosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2543-2548.	6.7	148

#	ARTICLE	IF	CITATIONS
19	Evolution of treatment for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, vi28-vi36.	1.9	139
20	Incidence of Nephrogenic Systemic Fibrosis after Adoption of Restrictive Gadolinium-based Contrast Agent Guidelines. <i>Radiology</i> , 2011, 260, 105-111.	7.3	134
21	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1051-1057.	0.9	128
22	Treat-to-target (T2T) recommendations for gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 632-638.	0.9	118
23	The term “non-radiographic axial spondyloarthritis”™ is much more important to classify than to diagnose patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 791-794.	0.9	105
24	Current status of nephrogenic systemic fibrosis. <i>Clinical Radiology</i> , 2014, 69, 661-668.	1.1	100
25	The advent of biosimilar therapies in rheumatology—“Brave New World”. <i>Nature Reviews Rheumatology</i> , 2012, 8, 430-436.	8.0	97
26	Biosimilars in rheumatology: current perspectives and lessons learnt. <i>Nature Reviews Rheumatology</i> , 2015, 11, 713-724.	8.0	96
27	Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. <i>Radiology</i> , 2009, 253, 81-89.	7.3	95
28	Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. <i>Arthritis Research and Therapy</i> , 2014, 16, R40.	3.5	93
29	Rheumatic Manifestations of Diabetes Mellitus. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 681-699.	1.9	88
30	Î2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. <i>Kidney International</i> , 1998, 53, 1365-1373.	5.2	85
31	Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: Risk reduction in a chronic inflammatory disease. <i>Arthritis Care and Research</i> , 2011, 63, 512-521.	3.4	76
32	Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 489-503.	3.3	76
33	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 727-738.	0.9	76
34	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 538-546.	0.9	75
35	Î2-Microglobulin modified with advanced glycation end products delays monocyte apoptosis. <i>Kidney International</i> , 2001, 59, 990-1002.	5.2	71
36	A Fifty-two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1101-1111.	5.6	71

#	ARTICLE	IF	CITATIONS
37	Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. <i>Blood</i> , 2002, 99, 2259-2261.	1.4	68
38	Gadolinium-Induced Fibrosis. <i>Annual Review of Medicine</i> , 2016, 67, 273-291.	12.2	66
39	Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naïve patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1279-1284.	0.9	64
40	Advanced glycation endproducts and osteoarthritis. <i>Current Rheumatology Reports</i> , 2003, 5, 33-40.	4.7	60
41	Interaction between β_2 -microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. <i>Kidney International</i> , 1997, 51, 1514-1519.	5.2	58
42	Case 6-2008. <i>New England Journal of Medicine</i> , 2008, 358, 827-838.	27.0	57
43	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1671-1679.	0.9	53
44	Biosimilars to treat inflammatory arthritis: the challenge of proving identity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1589-1593.	0.9	52
45	Biosimilars: a regulatory perspective from America. <i>Arthritis Research and Therapy</i> , 2011, 13, 112.	3.5	49
46	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor β inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015, 17, 14.	3.5	49
47	Utility of high-resolution ultrasound for the diagnosis of dialysis-related amyloidosis. <i>Arthritis and Rheumatism</i> , 1992, 35, 926-932.	6.7	47
48	Relapsing Polychondritis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 263-276.	1.9	45
49	Case 35-2004. <i>New England Journal of Medicine</i> , 2004, 351, 2219-2227.	27.0	42
50	Imaging for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 695-710.	1.9	40
51	Biosimilars in rheumatology: what the clinician should know. <i>RMD Open</i> , 2015, 1, e000010-e000010.	3.8	39
52	Separation of functionally distinct subpopulations of <i>Corynebacterium parvum</i> -activated macrophages with predominantly stimulatory or suppressive effect on the cell-mediated cytotoxic T cell response. <i>Cellular Immunology</i> , 1979, 42, 28-41.	3.0	37
53	Gadolinium-based compounds induce NLRP3-dependent IL- 1β production and peritoneal inflammation. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2062-2069.	0.9	37
54	Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 30, 1335-1340.	3.4	36

#	ARTICLE	IF	CITATIONS
55	The Science Behind Biosimilars. Arthritis and Rheumatology, 2018, 70, 334-344.	5.6	36
56	Development of Gastrointestinal I^{22} -Microglobulin Amyloidosis Correlates With Time on Dialysis. American Journal of Surgical Pathology, 1998, 22, 729-735.	3.7	36
57	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the Rheumatic Diseases, 2019, 78, 872-878.	0.9	36
58	Rituximab biosimilars. Expert Opinion on Biological Therapy, 2013, 13, 1049-1062.	3.1	34
59	Nephrogenic Systemic Fibrosis: A Pathologic Study of Autopsy Cases. Archives of Pathology and Laboratory Medicine, 2009, 133, 1943-1948.	2.5	34
60	Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Annals of the Rheumatic Diseases, 2008, 67, iii66-iii69.	0.9	33
61	Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Journal of Rheumatology, 2016, 43, 2120-2130.	2.0	33
62	Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis and Rheumatology, 2017, 69, 1741-1750.	5.6	32
63	E-selectin, Interleukin 18, Serum Amyloid A, and Matrix Metalloproteinase 9 Are Associated with Clinical Response to Golimumab plus Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Journal of Rheumatology, 2009, 36, 1371-1379.	2.0	30
64	Osteoarticular disorders of renal origin: disease-related and iatrogenic. Best Practice and Research in Clinical Rheumatology, 2000, 14, 285-305.	3.3	29
65	Nephrogenic systemic fibrosis: An epidemic of gadolinium toxicity. Current Rheumatology Reports, 2008, 10, 195-204.	4.7	29
66	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Annals of the Rheumatic Diseases, 2014, 73, 1811-1818.	0.9	29
67	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology, 2013, 52, 1845-1855.	1.9	28
68	Golimumab: A novel human anti-TNF- α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evidence, 2010, 4, 159.	4.7	27
69	Synovial fluid eosinophilia in lyme disease. Arthritis and Rheumatism, 1988, 31, 1384-1389.	6.7	25
70	Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-scale Survey of Social Media Platforms. Arthritis Care and Research, 2019, 71, 323-330.	3.4	25
71	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open, 2020, 6, e001370.	3.8	23
72	Case 39-2006. New England Journal of Medicine, 2006, 355, 2678-2689.	27.0	22

#	ARTICLE	IF	CITATIONS
73	Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Rheumatology</i> , 2013, 52, 560-567.	1.9	22
74	Biosimilars: implications for rheumatoid arthritis therapy. <i>Current Opinion in Rheumatology</i> , 2017, 29, 260-268.	4.3	22
75	Aminoguanidine inhibits advanced glycation end products formation on beta2-microglobulin.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 277-283.	6.1	22
76	Assessment of control of rheumatoid arthritis disease activity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 497-507.	3.3	20
77	Clinical trials of biosimilars should become more similar. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 4-6.	0.9	20
78	Primary care physician perspectives on barriers to diagnosing axial Spondyloarthritis: a qualitative study. <i>BMC Family Practice</i> , 2020, 21, 204.	2.9	18
79	Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study. <i>Arthritis Research and Therapy</i> , 2021, 23, 51.	3.5	18
80	Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?. <i>BioDrugs</i> , 2020, 34, 723-732.	4.6	18
81	Health Canada/BIOTEC Canada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012. <i>Biologicals</i> , 2012, 40, 517-527.	1.4	17
82	The "Treat to Target" Approach to Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 487-504.	1.9	17
83	Case 31-2005. <i>New England Journal of Medicine</i> , 2005, 353, 1605-1613.	27.0	16
84	Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 1143-1156.	1.9	16
85	Enhancement of human monocyte beta-glucan receptors by glucocorticoids. <i>Immunology</i> , 1994, 81, 96-102.	4.4	16
86	Methotrexate: the gold standard without standardisation. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1081-1082.	0.9	15
87	Gadolinium and systemic fibrosis: guilt by association. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1895-1897.	0.9	15
88	Musculoskeletal manifestations in β_2 -microglobulin amyloidosis. Case discussion. <i>Arthritis and Rheumatism</i> , 1992, 35, 592-602.	6.7	14
89	Sensorineural Hearing Loss following Imatinib (Gleevec) Administration. <i>Otolaryngology - Head and Neck Surgery</i> , 2012, 146, 335-337.	1.9	14
90	Non-crystalline and crystalline rheumatic disorders in chronic kidney disease. <i>Current Rheumatology Reports</i> , 2008, 10, 235-248.	4.7	13

#	ARTICLE	IF	CITATIONS
91	Physician ability to assess rheumatoid arthritis disease activity using an electronic medical recordâ€‘based disease activity calculator. Arthritis and Rheumatism, 2009, 61, 495-500.	6.7	13
92	A rheumatologyâ€‘specific informaticsâ€‘based application with a disease activity calculator. Arthritis and Rheumatism, 2009, 61, 488-494.	6.7	13
93	Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: Aâ€‘diagnostic aid. Journal of the American Academy of Dermatology, 2011, 64, 741-747.	1.2	13
94	Biosimilars: New or DÃ©jÃ Vu?. Arthritis and Rheumatology, 2016, 68, n/a-n/a.	5.6	13
95	Differential Expression of Hedgehog and Snail in Cutaneous Fibrosing Disorders. American Journal of Clinical Pathology, 2016, 146, 709-717.	0.7	13
96	Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis and Rheumatology, 2020, 72, 1067-1071.	5.6	13
97	The Association of Relapsing Polychondritis and Myelodysplastic Syndrome: Report of Three Cases. Journal of Clinical Rheumatology, 2000, 6, 146-149.	0.9	12
98	Examining Treatment Decisionâ€‘Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. ACR Open Rheumatology, 2020, 2, 391-400.	2.1	12
99	Î²2-microglobulin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 187-211.	3.0	11
100	Case 37-2009. New England Journal of Medicine, 2009, 361, 2166-2176.	27.0	11
101	Pharmacokinetic equivalence of CTâ€‘P17 to highâ€‘concentration (100Â‘mg/ml) reference adalimumab: A randomized phase I study in healthy subjects. Clinical and Translational Science, 2021, 14, 1280-1291.	3.1	11
102	Gadolinium and nephrogenic systemic fibrosis: The evidence of things not seen. Cleveland Clinic Journal of Medicine, 2008, 75, 112-117.	1.3	11
103	Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. Rheumatology, 2014, 53, 1613-1617.	1.9	10
104	Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis. Current Rheumatology Reports, 2016, 18, 72.	4.7	10
105	Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis. Rheumatology, 2022, 61, 1385-1395.	1.9	10
106	Case 4-2006. New England Journal of Medicine, 2006, 354, 623-630.	27.0	9
107	Biosimilar switching â€‘To set a form upon desired changeâ€‘. Nature Reviews Rheumatology, 2017, 13, 391-392.	8.0	9
108	PANLAR consensus statement on biosimilars. Clinical Rheumatology, 2019, 38, 1485-1496.	2.2	9

#	ARTICLE	IF	CITATIONS
109	Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1015-1030.	2.3	9
110	Performance characteristics of a dialysis-related amyloidosis questionnaire.. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 1235-1240.	6.1	8
111	Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 349-354.	0.9	7
112	Clinical trial and "real-world" data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e44-e44.	0.9	7
113	Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4323-4333.	2.4	7
114	Wegener's granulomatosis: Is biologic therapy useful?. <i>Current Rheumatology Reports</i> , 2006, 8, 303-311.	4.7	6
115	OP0012...A Phase 3, Randomized, Double-Blind, Active Comparator Study of the Efficacy and Safety of Bow015, A Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 64.1-64.	0.9	6
116	Physical activity and attitudes and perceptions towards physical activity in patients with spondyloarthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 289-302.	3.4	6
117	Primary care physician perspectives on screening for axial spondyloarthritis: A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0252018.	2.5	6
118	Beta2-microglobulin amyloidosis in renal failure: Understanding this recently recognized condition. <i>Cleveland Clinic Journal of Medicine</i> , 1999, 66, 145-147.	1.3	6
119	Identification and characterization of opsonic fibronectin in synovial fluids of patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1991, 34, 687-696.	6.7	5
120	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 465-476.	1.9	5
121	The disease burden of axial spondyloarthritis: through a gendered lens. <i>Clinical Rheumatology</i> , 2022, 41, 1115-1124.	2.2	5
122	Patient perspectives on health care provider practices leading to an axial spondyloarthritis diagnosis: an exploratory qualitative research study. <i>BMC Family Practice</i> , 2021, 22, 251.	2.9	5
123	Fibrosis-Associated Single-Nucleotide Polymorphisms in TGFB1 and CAV1 Are Not Associated With the Development of Nephrogenic Systemic Fibrosis. <i>American Journal of Dermatopathology</i> , 2013, 35, 351-356.	0.6	4
124	FRI0211...Safety and efficacy of subcutaneous golimumab in chinese patients with active rheumatoid arthritis despite mtx therapy: results from a randomized, placebo-controlled, phase 3 trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A444.2-A444.	0.9	4
125	Brief Report: Development and Validation of a Semiautomated Method to Measure Erosion Volume in Inflammatory Arthritis by Computed Tomography Scanning. <i>Arthritis and Rheumatology</i> , 2016, 68, 332-336.	5.6	4
126	THU0202...Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A232.1-A232.	0.9	3

#	ARTICLE	IF	CITATIONS
127	Effects of baricitinib on haematological laboratory parameters in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	1.9	3
128	A “wind of change” to biosimilars: The <scp>NOR</scp>â€<scp>SWITCH</scp> trial and its extension. <i>Journal of Internal Medicine</i> , 2019, 285, 693-695.	6.0	3
129	Overcoming barriers to biosimilars in inflammatory arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 65-66.	8.0	3
130	Healing of erosions in rheumatoid arthritis remains elusive: results with 24 months of the anabolic agent teriparatide. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 11-14.	1.1	3
131	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 338-346.	0.6	3
132	Anesthesia for Open Lung Biopsy in a Patient with Intracardiac Tumor. <i>Anesthesiology</i> , 1989, 71, 607-610.	2.5	2
133	Vascular Occlusion and Cardiac Conduction Disturbances in a Patient Undergoing Peritoneal Dialysis. <i>Seminars in Dialysis</i> , 1993, 6, 135-139.	1.3	2
134	What Causes Nephrogenic Systemic Fibrosis?. <i>Dialysis and Transplantation</i> , 2008, 37, 95-98.	0.2	2
135	Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis. <i>Arthritis Care and Research</i> , 2013, 65, 637-642.	3.4	2
136	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 270-275.	1.1	2
137	Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. <i>Journal of Rheumatology</i> , 2021, 48, 513-519.	2.0	2
138	CMR2009: 5.04: Post-mortem analysis of gadolinium distribution in NSF subjects. <i>Contrast Media and Molecular Imaging</i> , 2009, 4, 274-274.	0.8	1
139	Erosion defined: back to basics. <i>Nature Reviews Rheumatology</i> , 2013, 9, 323-324.	8.0	1
140	THU0444â€¦Assessment of Global Disease Activity in RA by Patients and Physicians: Cultural Differences across Countries in the Meteor Database. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 336.2-336.	0.9	1
141	SAT0151â€¦Safety Profile of BOW015, A Biosimilar Infliximab, In Healthy Subjects and Patients with Active Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 706.2-706.	0.9	1
142	Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 125-132.	0.7	1
143	Disease Burden and Health-Related Quality of Life Among Women and Men with Spondyloarthritis: An Exploratory Analysis of a Population-Based Sample. <i>Journal of Women's Health</i> , 2021, 30, 1637-1644.	3.3	1
144	AB0198â€¦EFFICACY AND SAFETY AFTER TRANSITION FROM REFERENCE ADALIMUMAB TO CT-P17 (ADALIMUMAB) Tj ETQqO 0 0 rgBT <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1123-1124.	0.9	1

#	ARTICLE	IF	CITATIONS
145	Nephrogenic Systemic Fibrosis. , 2014, , 247-254.		1
146	Knowledge of biosimilars and perceptions of the naming conventions for biosimilar products in clinical practice in the United States. Drugs and Therapy Perspectives, 2021, 37, 338-346.	0.6	1
147	Development of a screening tool to identify patients with axial spondyloarthritis: a cognitive interview study. Clinical Rheumatology, 2022, , 1.	2.2	1
148	Development and testâ€“retest reliability of a screening tool for axial spondyloarthritis. PLoS ONE, 2022, 17, e0269494.	2.5	1
149	Shoulder Pain in the Dialysis Patient. Seminars in Dialysis, 1995, 8, 105-121.	1.3	0
150	Nephrogenic Fibrosing Dermopathy: A Review of the Massachusetts General Hospital Experience. Journal of Cutaneous Pathology, 2005, 32, 89-89.	1.3	0
151	Nephrogenic systemic fibrosis: a new concern for rheumatologists. Nature Clinical Practice Rheumatology, 2008, 4, 445-445.	3.2	0
152	Treating rheumatoid arthritis to target: an international initiative. Current Reviews in Musculoskeletal Medicine, 2011, 4, 79-83.	3.5	0
153	Preface. Rheumatic Disease Clinics of North America, 2013, 39, xv-xvi.	1.9	0
154	FRI0096â€“...Haq baseline values in an international registry of ra patients during the era of biologic therapies: the 2013 meteor database.. Annals of the Rheumatic Diseases, 2013, 72, A402.1-A402.	0.9	0
155	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. International Journal of Clinical Rheumatology, 2015, 10, 425-431.	0.3	0
156	THU0138â€“...Secondary Efficacy Results Up To Week 24 from A Phase III Study Comparing SB5 (An) Tj ETQq0 0 0 rgBT /Overlock 10 Tf . Rheumatoid Arthritis despite Methotrexate Therapy. Annals of the Rheumatic Diseases, 2016, 75, 231.1-231.	0.9	0
157	OP0203â€“...Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf .		
158	Reply. Arthritis and Rheumatology, 2018, 70, 476-476.	5.6	0
159	THU0184â€“...Impact of immunogenicity on clinical efficacy and administration related reaction in tn timer inhibitors: a pooled-analysis from three biosimilar studies in patients with rheumatoid arthritis. , 2018, , .		0
160	SAT0162â€“...A POOLED ANALYSIS OF 1-YEAR CLINICAL OUTCOMES AMONG 6-MONTH RESPONDERS AND NON-RESPONDERS FROM THREE RANDOMISED CONTROLLED STUDIES OF TNF INHIBITOR BIOSIMILARS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
161	Hand Rheumatoid Arthritis. , 2020, , 179-184.		0
162	A Time-Response Measure to Assess Clinical Equivalence in Rheumatoid Arthritis: An Assessment Using Data From Clinical Trials of Biosimilars. Statistics in Biopharmaceutical Research, 2020, , 1-13.	0.8	0

#	ARTICLE	IF	CITATIONS
163	AB0892-HPRâ€...PATIENT PERSPECTIVES ON PROVIDER PRACTICES LEADING TO AN AXIAL SPONDYLOARTHRITIS DIAGNOSIS: A QUALITATIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1469.2-1470.	0.9	0
164	POS1474-HPRâ€...PERSONAL EXPERIENCES WITH DIAGNOSTIC DELAY AMONG AXIAL SPONDYLOARTHRITIS PATIENTS â€“ A QUALITATIVE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1022.2-1022.	0.9	0
165	FRI0002â€...Il-1 receptor antagonist (il-1ra) treatment is associated with improvement of anaemia in rheumatoid arthritis. , 2001, , .		0
166	Miscellaneous arthropathies. , 2015, , 1420-1431.		0
167	Gadolinium-Induced Fibrosis. Rare Diseases of the Immune System, 2017, , 209-237.	0.1	0
168	Controversies in Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xv-xvi.	1.9	0
169	Lyme disease. Comprehensive Therapy, 1993, 19, 157-62.	0.2	0